Open Access

Diagnostic value of molybdenum target combined with DCE-MRI in different types of breast cancer

  • Authors:
    • Ying Hu
    • Yan Zhang
    • Jingliang Cheng
  • View Affiliations

  • Published online on: August 14, 2019     https://doi.org/10.3892/ol.2019.10746
  • Pages: 4056-4063
  • Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

This study compared the diagnostic value of molybdenum target and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in different types of breast cancer. A retrospective analysis was performed on 120 female patients with breast cancer admitted to The First Affiliated Hospital of Zhengzhou University from February 2015 to October 2017. All of them underwent DCE-MRI and molybdenum target examination. Postoperatively, the pathological tissues were examined to determine their molecular typing. The sensitivity and diagnostic coincidence rates of Luminal-B breast cancer with different molecular types diagnosed by molybdenum target combined with DCE-MRI were significantly higher than those of molybdenum target or DCE-MRI alone. There were no statistical differences in sensitivity and diagnostic coincidence rates of breast cancer with different molecular types diagnosed by molybdenum target or DCE-MRI alone between the two groups (P>0.05). Molybdenum target combined with DCE-MRI in the diagnosis of different molecular types of breast cancer is better than the single imaging screening, which is of great clinical significance in the development of individualized comprehensive treatment for breast cancer patients and worthy of wide promotion in clinical practice.

References

1 

Lantz PM and Booth KM: The social construction of the breast cancer epidemic. Soc Sci Med. 46:907–918. 1998. View Article : Google Scholar : PubMed/NCBI

2 

Vallance JK, Courneya KS, Plotnikoff RC and Mackey JR: Analyzing theoretical mechanisms of physical activity behavior change in breast cancer survivors: Results from the activity promotion (ACTION) trial. Ann Behav Med. 35:150–158. 2008. View Article : Google Scholar : PubMed/NCBI

3 

DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO and Jemal A: International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 24:1495–1506. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Kitamura T, Qian BZ, Soong D, Cassetta L, Noy R, Sugano G, Kato Y, Li J and Pollard JW: CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med. 212:1043–1059. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Chee W, Lee Y, Im EO, Chee E, Tsai HM, Nishigaki M, Yeo SA, Schapira MM and Mao JJ: A culturally tailored Internet cancer support group for Asian American breast cancer survivors: A randomized controlled pilot intervention study. J Telemed Telecare. 23:618–626. 2017. View Article : Google Scholar : PubMed/NCBI

6 

Stuart-Harris R, Dahlstrom JE, Gupta R, Zhang Y, Craft P and Shadbolt B: Recurrence in early breast cancer: Analysis of data from 3,765 Australian women treated between 1997 and 2015. Breast. 44:153–159. 2019. View Article : Google Scholar : PubMed/NCBI

7 

Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 11:5678–5685. 2005. View Article : Google Scholar : PubMed/NCBI

8 

Edenfield J, Schammel C, Collins J, Schammel D and Edenfield WJ: Metaplastic breast cancer: Molecular typing and identification of potential targeted therapies at a single institution. Clin Breast Cancer. 17:e1–e10. 2017. View Article : Google Scholar : PubMed/NCBI

9 

Chou R, Cuevas C, Fu R, Devine B, Wasson N, Ginsburg A, Zakher B, Pappas M, Graham E and Sullivan SD: Imaging techniques for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. Ann Intern Med. 162:697–711. 2015. View Article : Google Scholar : PubMed/NCBI

10 

Ohuchi N, Suzuki A, Sobue T, Kawai M, Yamamoto S, Zheng YF, Shiono YN, Saito H, Kuriyama S, Tohno E, et al J-START investigator groups, : Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): A randomised controlled trial. Lancet. 387:341–348. 2016. View Article : Google Scholar : PubMed/NCBI

11 

Brem RF, Lenihan MJ, Lieberman J and Torrente J: Screening breast ultrasound: Past, present, and future. AJR Am J Roentgenol. 204:234–240. 2015. View Article : Google Scholar : PubMed/NCBI

12 

Huang Q, Luo Y and Zhang Q: Breast ultrasound image segmentation: A survey. Int J CARS. 12:493–507. 2017. View Article : Google Scholar

13 

Xia W, Yan Z and Gao X: Volume fractions of DCE-MRI parameter as early predictor of histologic response in soft tissue sarcoma: A feasibility study. Eur J Radiol. 95:228–235. 2017. View Article : Google Scholar : PubMed/NCBI

14 

Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D and Lawrentschuk N: Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 70:926–937. 2016. View Article : Google Scholar : PubMed/NCBI

15 

Zhao H, Zou L, Geng X and Zheng S: Limitations of mammography in the diagnosis of breast diseases compared with ultrasonography: A single-center retrospective analysis of 274 cases. Eur J Med Res. 20:492015. View Article : Google Scholar : PubMed/NCBI

16 

Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, et al ABCTB Investigators; kConFab/AOCS Investigators; NBCS Collaborators, : Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet. 104:21–34. 2019. View Article : Google Scholar : PubMed/NCBI

17 

Christiansen P, Bjerre K, Ejlertsen B, Jensen MB, Rasmussen BB, Lænkholm AV, Kroman N, Ewertz M, Offersen B, Toftdahl DB, et al Danish Breast Cancer Cooperative Group, : Mortality rates among early-stage hormone receptor-positive breast cancer patients: A population-based cohort study in Denmark. J Natl Cancer Inst. 103:1363–1372. 2011. View Article : Google Scholar : PubMed/NCBI

18 

Jafari SH, Saadatpour Z, Salmaninejad A, Momeni F, Mokhtari M, Nahand JS, Rahmati M, Mirzaei H and Kianmehr M: Breast cancer diagnosis: Imaging techniques and biochemical markers. J Cell Physiol. 233:5200–5213. 2018. View Article : Google Scholar : PubMed/NCBI

19 

Montes de Oca R, Gurard-Levin ZA, Berger F, Rehman H, Martel E, Corpet A, de Koning L, Vassias I, Wilson LO, Meseure D, et al: The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma. Mol Oncol. 9:657–674. 2015. View Article : Google Scholar : PubMed/NCBI

20 

Chen L, Li CI, Tang MT, Porter P, Hill DA, Wiggins CL and Cook LS: Reproductive factors and risk of luminal, HER2-overexpressing, and triple-negative breast cancer among multiethnic women. Cancer Epidemiol Biomarkers Prev. 25:1297–1304. 2016. View Article : Google Scholar : PubMed/NCBI

21 

Gallardo A, Garcia-Valdecasas B, Murata P, Teran R, Lopez L, Barnadas A and Lerma E: Inverse relationship between Ki67 and survival in early luminal breast cancer: Confirmation in a multivariate analysis. Breast Cancer Res Treat. 167:31–37. 2018. View Article : Google Scholar : PubMed/NCBI

22 

Adriaenssens E, Vanhecke E, Saule P, Mougel A, Page A, Romon R, Nurcombe V, Le Bourhis X and Hondermarck H: Nerve growth factor is a potential therapeutic target in breast cancer. Cancer Res. 68:346–351. 2008. View Article : Google Scholar : PubMed/NCBI

23 

Li H, Zhu Y, Burnside ES, Huang E, Drukker K, Hoadley KA, Fan C, Conzen SD, Zuley M, Net JM, et al: Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. NPJ Breast Cancer. 2:22016. View Article : Google Scholar

24 

Goffin J, Chappuis PO, Wong N and Foulkes WD: Re: Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst. 93:1754–1755. 2001. View Article : Google Scholar : PubMed/NCBI

25 

Shao H, Li B, Zhang X, Xiong Z, Liu Y and Tang G: Comparison of the diagnostic efficiency for breast cancer in Chinese women using mammography, ultrasound, MRI, and different combinations of these imaging modalities. J Xray Sci Technol. 21:283–292. 2013.PubMed/NCBI

26 

Shimauchi A, Jansen SA, Abe H, Jaskowiak N, Schmidt RA and Newstead GM: Breast cancers not detected at MRI: Review of false-negative lesions. AJR Am J Roentgenol. 194:1674–1679. 2010. View Article : Google Scholar : PubMed/NCBI

27 

Bäuerle T, Bartling S, Berger M, Schmitt-Gräff A, Hilbig H, Kauczor HU, Delorme S and Kiessling F: Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis. Eur J Radiol. 73:280–287. 2010. View Article : Google Scholar : PubMed/NCBI

28 

Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, et al Magnetic Resonance Imaging Screening Study Group, : Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 351:427–437. 2004. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 18 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Hu, Y., Zhang, Y., & Cheng, J. (2019). Diagnostic value of molybdenum target combined with DCE-MRI in different types of breast cancer. Oncology Letters, 18, 4056-4063. https://doi.org/10.3892/ol.2019.10746
MLA
Hu, Y., Zhang, Y., Cheng, J."Diagnostic value of molybdenum target combined with DCE-MRI in different types of breast cancer". Oncology Letters 18.4 (2019): 4056-4063.
Chicago
Hu, Y., Zhang, Y., Cheng, J."Diagnostic value of molybdenum target combined with DCE-MRI in different types of breast cancer". Oncology Letters 18, no. 4 (2019): 4056-4063. https://doi.org/10.3892/ol.2019.10746